HOME > ARCHIVE

ARCHIVE

Janssen Pharm. Posts Strong Growth in 2004

April 4, 2005
BI Extends Collaboration with MorphoSys AG

April 4, 2005
Meiji Yakuhin Completes New Contract Mfg Plant

April 4, 2005
Alfresa HD Aims at Sales of \1,385 Bil. in 2008

April 4, 2005
Korosho to Start Major Studies on Diabetes and Depression

April 4, 2005
No Big Increase in Business with Sankyo in Near Term: Mediceo

April 4, 2005
RESEARCH & DEVELOPMENT NEWS IN BRIEF

April 4, 2005
BUSINESS NEWS IN BRIEF

April 4, 2005
Surveys on Effects of DPC on Use of Generics, Readmission Rate

April 4, 2005
PRESS SEMINAR

April 4, 2005
MONITAR

April 4, 2005
The Reporter's Eye: 1

April 4, 2005
MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

April 4, 2005
MEETING

April 4, 2005
Hospitals' Attitudes toward Health Foods Vary: Survey

April 4, 2005
Gov't Approves 3-year Plan for Regulatory Reform

April 4, 2005
DIAGNOSTIC NEWS IN BRIEF

April 4, 2005
Korosho to Relax Approval Requirements for Combination Drugs

April 4, 2005
The Reporter's Eye: 2

April 4, 2005
Recommendation on Use of Iressa Compiled

April 4, 2005

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…